The genomic landscape of adenomas and polyps may help define disease pathways. Expression of miRNAs in adenomas and polyps may importantly contribute to these pathways. We evaluated miRNA expression in 293 polyp-normal colorectal mucosa pairs. Polyps were classified as either adenomatous polyp (AD), hyperplastic polyp (HP), or sessile serrated polyp (SSP). We compared these miRNA expression profiles in polyps to miRNA expression in microsatellite unstable (MSI) and stable (MSS) tumors. A False Discovery Rate of 0.05 based on Benjamini and Hochberg was used to adjust for multiple comparisons. There were 70 miRNAs with differential expression by polyp type with a fold change <0.75 or >1.34 after adjusting for multiple comparisons. The major differences in miRNA expression were observed between AD and SSP and AD and HP, with few differences in expression noted for SSP and HP. AD polyps were more likely to be upregulated from normal colonic mucosa, while SSP and HP were more likely to be downregulated from normal colonic mucosa. MiRNA expression in the SSP and HP tumors almost uniformly go in opposite directions from the MSS tumor miRNA expression and was mixed with MSI tumors. We conclude that different types of polyps have unique miRNA expression profiles.
INTRODUCTION
Certain types of colorectal polyps are thought to be precursor lesions for colorectal carcinomas (CRC). The histological characteristics of polyps are thought to be related to unique pathways to CRC (Jass, 2007a,b) . For example, sessile serrated polyps (SSP) have been linked to CpG island methylator phenotype (CIMP) high, MSI high and BRAF-mutated tumors, while the more common adenoma carcinoma sequence has been linked to microsatellite stable tumors (Jass, 2007b) . Hyperplastic polyps (HP), usually considered as a noncarcinoma precursor, have some overlapping characteristics with SSP's. The molecular signature of polyps may be important in identifying clinical and molecular features of subsequent carcinomas.
MiRNAs are small, non-protein-coding RNA molecules that regulate gene expression (Ambros, 2004; Gartel and Kandel, 2008] . We have previously shown that miRNAs are commonly dysregulated in CRC and that some miRNAs are dysregulated as the tumor progresses, i.e., some are expressed differently in adenoma than in normal mucosa but have similar levels of expression in cancers, while others are similar in expression to normal mucosa but different from carcinoma expression (Slattery et al., 2016a) . Additionally, we have shown that differences in miRNA expression by tumor molecular phenotype exist (Slattery et al., 2016b) .
In this study we examined miRNA expression profiles in polyp subtypes, evaluating adenomatous polyps (AD), SSP, and HP. We did this to determine similarities and differences in polyp types as well as their alignment with MSI tumors. Thus, we compared miRNA expression between polyp subtype and MSI and MSS miRNA expression profiles. Our goal was to identify miRNAs that can help characterize MSI or MSS molecular pathways of CRC and help describe the genomic landscape of polyps.
MATERIALS AND METHODS

Study Participants
The study was approved by the Institutional Review Board of the University of Utah; study participants signed informed consent. Study participants came from two population-based casecontrol studies that included all incident colon and rectal cancers between 30 and 79 years of age who resided along the Wasatch Front in Utah or were members of the Kaiser Permanente Medical Care Program in Northern California (Slattery et al., 1997 (Slattery et al., , 2003 . Cases had to have tumor registry verification of a first primary adenocarcinoma of the colon or rectum and were diagnosed between October 1991 and September 1994 for the colon cancer and between June 1997 and May 2001 for the rectal cancer. Individuals with familial adenomatous polyposis coli, inflammatory bowel disease, Crohn's disease, and known Lynch Syndrome were excluded. Tumor tissue was obtained for 97% of all Utah cases diagnosed and for 85% of all Kaiser Permanente Medical Care Program in Northern California study participants (Slattery et al., 2000a) . Detailed study methods have been described (Slattery et al., 2016a) . The study population available to examine miRNA profiles in synchronous adenomas included 293 samples with either an AD, SSP, or HP. Of the 293 individual pathologies reviewed, 265 individuals only had AD polyps, eight individuals had SSP only, seven individuals had an HP only, five individuals had both an AD and SSP, seven individuals had both an AD and HP, and one person had both an SSP and HP.
miRNA Processing
RNA was extracted from formalin-fixed paraffin embedded tissue using Ambion's RecoverAll Total Nucleic Acid isolation kit. Normal mucosa adjacent to the carcinoma tissue was used. The Agilent Human miRNA Microarray V19.0 was used given the number of miRNAs, its high level of reliability (repeatability coefficient was 0.98 in our data) and the amount of RNA needed to run the platform. The microarray contains probes for 2006 unique human miRNAs. Data were required to pass stringent quality control parameters established by Agilent that included tests for excessive background fluorescence, excessive variation among probe sequence replicates on the array, and measures of the total gene signal on the array to assess low signal. The Agilent platform was shown to have high repeatability (r 5 0.98) and good correlation with other platforms such as Nanostring (Slattery et al., 2016a) . Other analysis of a subset of 22 important miRNAs showed 100% agreement in terms of directionality of differential expression and fold change when comparing results from the Agilent platform to those obtained from qPCR (Pellatt et al., 2016) . While the results were identical in terms of directionality and Agilent platform often slightly underestimated the fold change detected in qPCR analysis.
Tumor Molecular Phenotype
We have previously evaluated microsatellite instability by the mononucleotide repeats BAT26 and TGFbR2 and a panel of 10 tetranucleotide repeats that were correlated highly with the Bethesda Panel (Slattery et al., 2000b) .
Statistical Methods
To normalize differences in miRNA expression that could be attributed to the array, amount of RNA, location on array, or other factors that could erroneously influence expression, total gene signal was normalized by multiplying each sample by a scaling factor (Agilent GeneSpring User Manual) (http://genespring-support.com/files/gs_12_6/Gene Spring-manual.pdf), which was the median of the 75 th percentiles of all the samples divided by the individual 75 th percentile of each sample. Data were log 2 transformed prior to analysis and were analyzed using the significance analysis of microarrays technique implemented in the R package siggenes (Tusher et al., 2001 ); P-values were based upon 1,000 permutations. Only miRNAs with a large percentage of samples expressing above the background were included. Comparisons were made between polyp type (AD, SSP, and HP) to assess miRNA expression differences. We compared differences based on both polyp miRNA expression as well as differential expression between polyp and normal colonic mucosa expression. To adjust for multiple comparisons we applied a False Discovery Rate (FDR) level of significance of 0.05 based on Benjamini and Hochberg (Benjamini et al., 1995) . Additionally, we evaluated miRNA expression by polyp type with both MSI and MSS tumors.
To visualize differences in expression by polyp subtype, first we compared differential expression between the three different polyp types and normal colonic mucosa using the two class test for paired polyp/normal mucosa data in siggenes, applied an FDR level of 0.05, and fold change less than log 2 (0.75) or greater than log 2 (1.5). Using these results we created heatmaps of the fold changes of the different polyp types in SAS 9.4. We recalculated the fold changes of the significant results comparing the MSI or MSS carcinoma samples and polyp samples to paired normal colonic mucosa results and created heatmaps of the fold changes of the different polyp types and MSI or MSS.
RESULTS
The majority of the study population was male (Table 1) . AD were somewhat equally distributed across colorectal tumor sites, while SSP was predominately in the proximal colon and HP was predominately from the rectum. The majority of AD polyps were associated with TP53-mutated and KRAS-mutated tumors, SSP were associated with MSI and CIMP tumors, while HP were associated mainly with either a TP53-mutated or CIMP high tumor.
The fold change (FC) between miRNA expression in tumor tissue by polyp type is shown in Table 2 for those miRNAs that were statistically significant after adjustment for multiple comparisons and for whom the FC was <0.75 or >1.34 for any of the comparisons. There were 70 miRNAs that met these criteria. The major differences in miRNA expression were observed between AD and SSP and AD and HP, with few differences in expression noted between SSP and HP.
Additionally, we evaluated significant differences in differential expression between polyp and normal mucosa by polyp subtype and identified an additional 19 miRNAs beyond those associated with miRNA expression in polyps that were differentially expressed between AD and HP (let-7i-5p, miR-1229-5p, miR-1234-5p, miR-1249, miR-1268B, miR-1275, miR-194-5p, miR-215, miR-2392, miR30b-5p, miR-331-3p, miR-3653, miR-3960, miR-4281, miR-4689, mR-4739, miR-518a-5p, miR-6510-5p , and miR-939-5p) when considering a FC of >1.34 or <0.75; there were no differences in differential expression between SSP and HP (data not shown in table).
Evaluation of the top dysregulated miRNAs by tissue type showed that miRNAs in AD polyp tissue were more likely to be upregulated from normal colonic mucosa, while miRNAs in SSP and HP tissue were more likely to be downregulated from normal colonic mucosa (Figure 1 ). While the AD is often not different from the normal mucosa, the SSP and HP are downregulated and the MSI tumor contain a mixture of upregulated, downregulated and not differentially expressed miRNAs. Looking at a similar comparison that includes MSS tumors miRNA expression in the SSP and HP polyps almost uniformly go in opposite directions from the MSS tumor miRNA expression.
We assessed molecular pathways that were uniquely associated with AD and with SSP/HP differential expression. In these analyses we included miRNAs that were significantly dysregulated with a fold change of 1.35 or greater or 0.74 or smaller and were significantly different between AD and SSP/HP adenoma subtype. There were many more pathways identified for SSP/HP than for AD. After adjustment for multiple comparisons there were nine canonical pathways with an adjusted -log2 P value of 2.00E00 for AD (See Supporting Information 1) while there were 143 canonical pathways associated with genes regulated by differentially expressed miRNAs for SSP/ HP. There was overlap in these pathways. For instance, both polyp types were associated with molecular mechanisms of cancer and TP53. However for AD the TP53 pathway appeared to be upregulated while for SSP/HP the pathway appeared to be downregulated based on the up and down regulation of the miRNAs in the adenoma tissue compared to normal colonic mucosa.
DISCUSSION
We observed differences in miRNA expression by polyp type, with adenomatous polyps being upregulated from normal colonic mucosa while miRNA expression in SSP and HP was usually downregulated. There were few differences in miRNA expression between SSP and HP. However, examining polyps in people who had both AD and HP, we observed fewer differences in miRNA expression by polyp type.
As possible precursors to colorectal carcinomas, polyps are potentially a major component of the carcinogenic process. While adenomatous polyps represent the majority of polyps that evolve into cancers, it is thought that some sessile serrated polyps contribute to unique disease pathways that include MSI tumors. Serrated polyps can be divided into hyperplastic polyps, considered to have no malignant potential, and the possibly premalignant sessile serrated polyp. Sessile serrated polyps are defined by their histologic appearance (Rex et al., 2012) ] and were described in the 1990s based on their serrated glandular configuration and other clinical-pathological features (Longacre and Fenoglio-Preiser, 1990) Our findings suggest the miRNA profiles of HP and SSP are very similar and support the conclusions of Sandmeier and colleagues that HP and SSP have similar genomic characteristics (Sandmeier et al., 2009 ). These polyps differ in miRNA expression profiles from AD and are more likely to have downregulated miRNA expression whereas AD are more likely to have upregulated miRNA expression. These miRNAs also were more likely to be downregulated relative to MSI tumors and inconsistently upregulated and downregulated with MSS tumors. Also of interest is the larger number of dysregulated miRNAs in SPP/HP than observed for AD and therefore the larger possible number of targeted dysregulated genes and their associated pathways.
At the population level, when comparing all AD to all SSP/HP we saw a large number of dysregulated miRNAs between these polyp types. However, for those few individuals that had both an AD and a SSP/HP we saw fewer miRNAs that were differentially expressed between the polyp types. It is possible that some of the differences could be from confounding variables that were We have a large set of polyps with paired carcinoma and normal colorectal mucosa tissue. All paired samples came from the same tumor location. We believe that these are strengths of the study. Additionally, by using the Agilent miRNA platform we were able to assess expression of over 2000 miRNAs in colorectal tissue. In addition to the miRNA data, we have data on tumor molecular phenotype and other lifestyle factors. However, the study has limitations. First the polyps are synchronous to the carcinoma and are not the precursor lesion. Thus we are able to look at characteristics of polyps with a certain miRNA profile and compare it to the miRNA profiles of other synchronous polyps and carcinoma miRNA profiles. Additionally given the number of targeted genes by these dysregulated miRNA, it is difficult to identify specific pathways that are unique to various polyp subtypes. This limitation is a limitation of the state of the field of miRNA bioinformatics at this time. Additionally we report results based on an arbitrary fold change cutoff of <0.75 or greater than 1.34 as well as statistical significance. It should be acknowledged that the biologically important fold change for each miRNA is not known and that miRNAs with lower levels of expression can have an absolute change in expression that is minimal, yet have a large fold change.
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